PolyPid

PolyPid EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of PolyPid (PYPD) as of Oct 11, 2026 is -2.14. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.51 — a change of -14.98% (higher).

EV/EBIT

-2.14

YoY

-14.98%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of PolyPid is 2025 -2.14 . EV/EBIT (Enterprise Value to EBIT) of PolyPid was 2024 -2.51 . It decreases by -14.98% higher compared to the previous year.

The PolyPid EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-3.79 USD
Jan 1, 2020
-2.68 USD
Jan 1, 2021
-1.64 USD
Jan 1, 2022
-1.81 USD
Jan 1, 2023
-3.09 USD
Jan 1, 2024
-2.51 USD
Jan 1, 2025
-2.14 USD
Jan 1, 2026 (e)
-3.17 USD
The PolyPid EV/EBIT history
YEAREV/EBITYoY
est-3.17+48.39%
-2.14-14.98%
-2.51-18.72%
-3.09+70.69%
-1.81+10.25%
-1.64-38.72%
-2.68-29.35%
-3.79-1.06%
-3.83-24.85%
-5.10-25.66%
-6.86+9.91%
-6.25—
Access this data via the Eulerpool API

PolyPid Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides PolyPid's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates PolyPid's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots PolyPid's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if PolyPid grows earnings faster than its peers.

PolyPid Stock analysis

What does PolyPid do? PolyPid Ltd is an innovative, emerging company in the field of biomedical technology based in Israel. The company was founded in 2008 and has since gained continuous recognition and growth. PolyPid's core business is the development and manufacturing of implantable polymer systems that contribute to wound healing. These polymer systems are specifically introduced into the affected area of the body and continuously release active substances to prevent infections and promote natural healing processes. PolyPid's business model is focused on effectively solving patients' problems. The company has developed a wide range of products and technologies that specifically target various medical applications. These include orthopedics, traumatology, urology, and gynecology. For orthopedics, PolyPid provides various products and technologies that can be used in knee and hip joint surgeries. These include antibiotic-releasing implants to prevent infections and resorbable bone fillers that allow for faster and more effective wound healing. In the field of traumatology, PolyPid manufactures polymer systems that are used in the treatment of bone fractures or other traumas. Here again, the polymer systems ensure continuous release of active substances to prevent infections and promote natural healing processes. PolyPid also offers innovative solutions for urology. Specifically, products are developed to combat urinary tract infections and promote faster wound healing after urological surgeries. For gynecology, PolyPid offers polymer systems that can be used particularly in the postoperative phase to prevent infections and achieve faster wound healing. PolyPid has earned an excellent reputation in the industry in recent years due to its consistent focus on innovation and quality. To continually improve their products, the company invests heavily in research and development and maintains close contact with medical institutions and professionals worldwide. PolyPid is an important partner in the field of biomedical technology and has already received numerous awards for its groundbreaking products and developments. Thanks to its focus on quality, reliability, and innovation, the company will continue to play a key role in the biomedical technology market. PolyPid is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PolyPid stock

EV/EBIT (Enterprise Value to EBIT) of PolyPid is -2.14 in 2025.

EV/EBIT (Enterprise Value to EBIT) of PolyPid changed from -2.51 to -2.14, representing a -14.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) PolyPid since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s PolyPid with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — PolyPid

All Key Metrics — PolyPid